Tau protease compositions and methods of use
AssigneeOligomerix, Inc.
InventorsJAMES G. MOE, ELIOT J. DAVIDOWITZ, PATRICIA LOPEZ
Life of this patent
Estimating the term…
Abstract
Disclosed are mammalian tau proteases, as well as proteolytically-active fragments, variants, and mutants thereof. Also disclosed are polynucleotides and recombinant expression vectors that encode these polypeptides, as well as methods for producing such proteins in selected recombinant host cells, and for using the compositions in a variety of diagnostic and analytical assays.
Claims22
An isolated peptide or polypeptide of about 50 to about 300 amino acids in length, comprising an amino acid sequence that is at least 95% identical to an at least 50-amino acid contiguous sequence from SEQ ID NO:6.
A tau protease variant peptide or polypeptide comprising an amino acid sequence of a starting mammalian tau protease that has been substituted in at least one amino acid at a position that corresponds to amino acid residue 5, 257, 260, 266, 272, 273, 279, 280, 285, 296, 301, 303, 304, 305, 315, 317, 320, 332, 335, 336, 337, 342, 352, 356, 363, 369, 389, 406, or 427 of SEQ ID NO:6, wherein the substitution confers to the protease variant peptide or polypeptide an enhanced serine protease activity, when compared to that of the original, un-substituted tau protease peptide or polypeptide.
An isolated peptide or polypeptide of about 50 to about 300 amino acids in length comprising an at least 40 contiguous amino acid sequence from SEQ ID NO:6, and that has been mutated at one or more amino acids that correspond to amino acid residue 5, 257, 260, 266, 272, 273, 279, 280, 285, 296, 301, 303, 304, 305, 315, 317, 320, 332, 335, 336, 337, 342, 352, 356, 363, 369, 389, 406, or 427 of SEQ ID NO:6, wherein the peptide or polypeptide has a serine protease activity that is at least 85% of that of the full-length Tau 4R2N trimer protease.
-41. (canceled)
Dependencies are inferred from the claim text.